Besides ibrutinib, sufferers with M-CLL, devoid of TP53 aberrations and match more than enough to tolerate FCR therapy, should still be great candidates for the latter, Along with the advantage getting that this cure is usually completed in six months while ibrutinib has to be taken indefinitely. This option could be significantly precious for non-